EpiCept Announces Q4 and Full Year 2012 Results

EpiCept Corporation (PINK:EPCT) has announced its operating and financial results, as well as its recent merger with Immune Pharmaceuticals, Ltd.

As quoted in the press release:

EpiCept’s net loss for the fourth quarter of 2012 was $0.9 million, or $0.01 per share, compared with a net loss of $3.5 million, or $0.05 per share for the fourth quarter of 2011. The net loss for the full year 2012 was $2.6 million, or $0.07 per share, compared with a net loss of $15.7 million, or $0.23 per share, for the full year 2011.

Click here to read the full EpiCept Corporation (PINK:EPCT) press release.